Last week I read that Oxford University’s Jenner Institute had completed Phase II trials for a malaria vaccine that demonstrated a 77% efficacy. Malaria affects 500 million people on the globe; annual deaths due to malaria are as high as 1 million per year. Most are among young children. Previous attempts to develop a vaccine have been hindered by the complexity of the malaria parasite—any of several species in the genus Plasmodium—which invades host cells and whose genome contains thousands of genes.
Malaria and Mosquitoes
2